LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Thirty-six patients with type 2 diabetes mellitus (T2DM) were randomized 1:1:1 to receive a once-daily oral dose of placebo or 150 or 300 mg of the dual SGLT1/SGLT2 inhibitor LX4211 for 28 days. Relative to placebo, LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Zambrowicz, B, Freiman, J, Brown, P M, Frazier, K S, Turnage, A, Bronner, J, Ruff, D, Shadoan, M, Banks, P, Mseeh, F, Rawlins, D B, Goodwin, N C, Mabon, R, Harrison, B A, Wilson, A, Sands, A, Powell, D R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400893/
https://www.ncbi.nlm.nih.gov/pubmed/22739142
http://dx.doi.org/10.1038/clpt.2012.58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400893/
https://www.ncbi.nlm.nih.gov/pubmed/22739142
http://dx.doi.org/10.1038/clpt.2012.58

Ejemplares similares